Daclahep

DaclaHep (Daclatasvir) is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.
U.S. Food and Drug Administration approved Daclatasvir for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections on July 24, 2015 . DaclaHep (Daclatasvir) is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.